Compare ARK Genomic Revolution ETF (ARKG) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Kinross Gold Corporation — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while Kinross Gold Corporation trades at $23.77 (market cap $28.72B). The key difference: Kinross Gold Corporation pays a 0.6% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Kinross Gold Corporation nearer its low. Which is the better fit depends on your goals.
| ARKG | KGC | |
|---|---|---|
Sector | Sector/Thematic | Basic Materials |
52-Week High | $43.57 | $38.06 |
52-Week Low | $23.09 | $15.33 |
Market Cap | — | $28.72B |
Enterprise Value | — | $27.28B |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
KGC trades at $24.14, down 0.25% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals, with revenue growing from $3.5B in 2022 to $7.05B in 2025 and net income surging to $2.39B. Valuation ratios are attractive, including a P/E of 10.27 and EV/EBITDA of 5.3. Recent earnings have consistently beaten expectations, and a dividend of $0.04 per share was declared for H1-26.
The outlook is positive due to robust cash flow growth, a healthy balance sheet, and analyst consensus favoring a buy rating with a $36.25 price target. Key risks include potential margin pressure from rising costs and broader market volatility affecting gold prices. The stock presents a value opportunity if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
